#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic graft versus host disease in intestine Autologous haematopoietic stem cell transplant Glioma Pemphigoid Congenital leptin deficiency Lymphangioma Follicle centre lymphoma follicular grade I, II – III Cardiac sarcoidosis Allogenic stem cell transplantation Transitional cell carcinoma Cytomegalovirus infection Oesophageal adenocarcinoma Glomerulonephritis minimal lesion Anti-myelin-associated glycoprotein associated polyneuropathy Leukocyte adhesion deficiency More trials…

    Learn about Rare Diseases

    Von Willebrand’s disease – Diagnostics Usher’s syndrome – Trials in Disease Urea cycle disorder – Diagnostics Factor VIII deficiency – Trials in Disease Arterial tortuosity syndrome Basal cell naevus syndrome – Life with Disease Haemolytic uraemic syndrome Langerhans cell sarcoma – Diagnostics Turner’s syndrome – Treatment CADASIL – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Nofazinlimab CARBACHOL Ampreloxetine Vericiguat Gskvx000000014593 Phenylephrine Hydrochloride Bms-986458 GSKVX000000040033 Omx-0407 Remdesivir Alfacalcidol Atuliflapon Toripalimab Bms-986288 Specific Nucleic Acid Sna-Xfsb Lerodalcibep Tilsotolimod Sodium Cebsulfase Alfa Benzylpenicillin Fluasterone More therapies…

    Learn about Your Condition

    Adrenoleukodystrophy Dry eye Glycogen storage disorder Ovarian cancer stage III Ejection fraction normal Cerebral amyloid angiopathy Anal cancer metastatic Mumps Thrombosis Strongyloidiasis Abdominal pain Ewing's sarcoma metastatic Endotracheal intubation C3 glomerulopathy Perthes disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm

  • Study on the Safety and Tolerability of TransCon IL-2 β/γ, Pembrolizumab, and Chemotherapy in Adults with Advanced or Metastatic Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Acp-017
    • Transcon Il-2Β/Γ
    • Pembrolizumab
    Belgium Italy Poland Spain

  • Study of BMS-986288 and Nivolumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Bms-986288
    • Regorafenib
    • Nivolumab
    France Italy Spain

  • Study of Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    Denmark France Germany Italy The Netherlands Norway +3

  • Study of MK-1088 and Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Mk-1088
    • Pembrolizumab
    Denmark

  • Study of CFT1946 alone and with trametinib or cetuximab in patients with BRAF-V600 mutant solid tumors who have received standard treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Cft1946
    • Cetuximab
    • Trametinib
    France Germany Italy Spain

  • Study of BMS-986408 Alone or with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Bms-986408
    • Ipilimumab
    • Nivolumab
    France Spain
Previous Page
1 … 21 22 23 24 25
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!